Market Overview

The Turkey pharmaceutical market size was valued at USD 21.4 Billion in 2024. It is projected to reach USD 32.5 Billion by 2033, growing at a CAGR of 4.28% during the forecast period from 2025 to 2033. Market growth is primarily driven by expanding healthcare access, a growing geriatric population, advancements in medical technology, and strategic investments by pharma companies.

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Turkey Pharmaceutical Market Key Takeaways

• The market size reached USD 21.4 Billion in 2024.
• The market is expected to grow at a CAGR of 4.28% during 2025-2033.
• The forecast period for the market extends from 2025 to 2033.
• The growing aging population in Turkey is driving increased demand for pharmaceuticals tailored to chronic diseases and geriatric care.
• Increased access to healthcare services and products authorized by ministries has significantly contributed to market expansion.
• Strategic investments by local and international pharmaceutical firms are enhancing healthcare accessibility and innovation.
• Advancements in medical technology continue to support industry growth.

Sample Request Link: https://www.imarcgroup.com/Turkey-Pharmaceutical-Market/requestsample

Market Growth Factors

The expanding elderly population is a critical factor propelling the Turkey pharmaceutical market. As per the Turkish Statistical Institute, the population aged 65 and over rose from 6,895,385 in 2017 to 8,451,669 in 2022, increasing by 22.6%. The elderly population's percentage grew from 8.5% in 2017 to 9.9% in 2022, with forecasts predicting a rise to 12.9% by 2030 and beyond. This demographic shift amplifies demand for drugs treating age-related illnesses such as cardiovascular diseases, diabetes, and arthritis, prompting pharmaceutical companies to focus on geriatric care and chronic disease management.

The enhanced accessibility of healthcare services has notably catalyzed market growth. According to ilac Endustrisi iseverenler Sendikasi (IEIS), Turkey's combined pharmaceutical and healthcare product market value surged to TRY 121.6 billion in 2022, marking a 78.8% growth. Unit sales increased by 8.6% to 2.82 billion units. Additionally, the healthcare market benefits from a wide range of products authorized by various ministries, including prescription drugs, health-specific foods, conventional herbal remedies, supplements, vitamins, and formulae. This broad availability stimulates consumption across specialty drugs and basic therapies.

Strategic investments by domestic and global pharmaceutical companies enhance technological advancement and production capabilities within Turkey. For example, the technology transfer agreement between Abdi İbrahim and mAbxience facilitates local biotech pharmaceutical manufacturing, improving supply chain resilience and healthcare access. Such collaborations reflect the sector's focus on innovation and sustainable growth. Concurrently, logistics providers like Turkish Cargo introducing tailored pharmaceutical shipment services, such as TK Pharma Standard, Extra, and Advanced, reshape the market by ensuring efficient distribution aligned with industry standards.

Market Segmentation

Type Insights:

• Pharmaceutical Drugs: Includes detailed categories such as Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorder Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, and Respiratory Diseases Drugs.
• Biologics: Encompasses Monoclonal Antibodies (MAbS), Therapeutic Proteins, and Vaccines.

Nature Insights:

• Organic: This segment covers pharmaceutical products derived from organic sources.
• Conventional: This segment includes traditionally manufactured pharmaceutical products.

Regional Insights:

• Marmara: A major regional market with significant pharmaceutical activities.
• Central Anatolia: Contributes notable pharmaceutical market share.
• Mediterranean: Active in pharmaceutical market development.
• Aegean: Recognized as a distinct pharmaceutical region.
• Southeastern Anatolia: Participates in the regional pharmaceutical market.
• Blacksea: Included in the market's geographic coverage.
• Eastern Anatolia: Part of the pharmaceutical market regional landscape.

Request Customization:

https://www.imarcgroup.com/request?type=report&id=24198&flag=E 

Regional Insights

The report identifies Marmara as one of the dominant pharmaceutical regions in Turkey. Although explicit market share percentages or CAGR are not provided, the Marmara region is included among key active regions such as Central Anatolia and Mediterranean. This broad geographic segmentation supports a comprehensive national market understanding, demonstrating varied regional contributions to overall pharmaceutical industry growth.

Recent Developments & News

On 20 November 2023, Abdi İbrahim announced a landmark technology transfer deal with biosimilar developer mAbxience. This collaboration aims to locally produce a monoclonal antibody for treating metastatic colorectal cancer and other cancers, enhancing local biotech pharmaceutical manufacturing. On 30 January 2024, Turkish Cargo introduced new pharmaceutical-focused logistics products TK Pharma Standard, TK Pharma Extra, and TK Pharma Advanced designed to provide flexible and specialized shipping solutions for diverse pharmaceutical and medical shipments across the market.

Key Players

• Abdi İbrahim
• mAbxience
• Turkish Cargo

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1-201971-6302